C (3-6 months) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR. 名古屋大学大学院医学系研究科・加藤昌志。(BALB/c x C57BL/6) X BALB/cへトランスジーンのインジェクションにより作出。C57BL/6およびBALB/cの混合背景。 Carrier x Noncarrier Carrier x Noncarrier 加藤　昌志 中部大学 Cancer Research Dermatology Research C（3〜6か月） メタロチオネインプロモーター制御下でがん遺伝子RETを発現するトランスジェニックマウス (ライン192) 。生後数ヶ月以内に皮膚に悪性転化しない良性メラノサイト系腫瘍を発症する (100％) 。紫外線照射により悪性黒色腫が誘導される。腫瘍発症およびがん化のメカニズムの解明に有用。, メタロチオネインプロモーター制御下でがん遺伝子RETを発現するトランスジェニックマウス (ライン192) 。生後数ヶ月以内に皮膚に悪性転化しない良性メラノサイト系腫瘍を発症する (100％) 。紫外線照射により悪性黒色腫が誘導される。腫瘍発症およびがん化のメカニズムの解明に有用。 <a href='https://brc.riken.jp/mus/pcr01707'>Genotyping protocol -PCR-</a> RBRC01707 true human RFP/RET cDNA, mouse MT-I promoter-enhancer, SV40 splicing signal-polyadenylation site, vector sequence Masashi KATO Developed by Masashi Kato, Nagoya University Graduate School of Medicine. The transgene was injected into the pronuclei of (BALB/c x C57BL/6) x BALB/c fertilized eggs. C57BL/6 and BALB/c mixed background. 192 RET 192 RET Mouse Models for Human Disease B6.Cg-Tg(Mt1-RET)192Ina B6.Cg-Tg(Mt1-RET)192Ina 条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>寄託者（開発者）の承諾を得る。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請及び事業活動を行う場合は、寄託者と別途協議を行う。共同研究。 Chubu Univ. This strain expresses the human RET gene under the control of the mouse Mt1 promoter/enhancer. This Mt1-RET 192 line develops benign tumors 100% within several months after birth. However they never transform to malignant tumors. Crossing with C57BL/6 multiple times makes this strain more difficult to maintain because of the earlier onset of tumors. Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol>